Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Michael E. Thase |
Documentos disponibles escritos por este autor (18)
Refinar búsqueda
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants / Michael E. Thase en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.9 (Septiembre)
[artículo]
Título : Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants : a phase 3, randomized, double-blind study Tipo de documento: texto impreso Autores: Michael E. Thase, Autor ; James M. Youakim, Autor ; Aleksandar Skuban, Autor Fecha de publicación: 2020 Artículo en la página: pp.1232-1240 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicoticos, Trastorno depresivo mayor, Trastorno depresivo resistente al tratamiento, Quinolonas, Tiofenos. Resumen: To evaluate efficacy, safety, and tolerability of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive disorder (as defined by DSM-IV-TR criteria) with inadequate response to ADTs. Link: ./index.php?lvl=notice_display&id=21881
in The Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.9 (Septiembre) . - pp.1232-1240[artículo] Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants : a phase 3, randomized, double-blind study [texto impreso] / Michael E. Thase, Autor ; James M. Youakim, Autor ; Aleksandar Skuban, Autor . - 2020 . - pp.1232-1240.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.9 (Septiembre) . - pp.1232-1240
Palabras clave: Antipsicoticos, Trastorno depresivo mayor, Trastorno depresivo resistente al tratamiento, Quinolonas, Tiofenos. Resumen: To evaluate efficacy, safety, and tolerability of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive disorder (as defined by DSM-IV-TR criteria) with inadequate response to ADTs. Link: ./index.php?lvl=notice_display&id=21881 Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants / Michael E. Thase en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.9 (Septiembre)
[artículo]
Título : Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants : a phase 3, randomized, double-blind study Tipo de documento: texto impreso Autores: Michael E. Thase, Autor ; James M. Youakim, Autor ; Aleksandar Skuban, Autor Fecha de publicación: 2020 Artículo en la página: pp.1232-1240 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicoticos, Trastorno depresivo mayor, Trastorno depresivo resistente al tratamiento, Quinolonas, Tiofenos. Resumen: To evaluate efficacy, safety, and tolerability of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive disorder (as defined by DSM-IV-TR criteria) with inadequate response to ADTs. Link: ./index.php?lvl=notice_display&id=21882
in The Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.9 (Septiembre) . - pp.1232-1240[artículo] Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants : a phase 3, randomized, double-blind study [texto impreso] / Michael E. Thase, Autor ; James M. Youakim, Autor ; Aleksandar Skuban, Autor . - 2020 . - pp.1232-1240.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.9 (Septiembre) . - pp.1232-1240
Palabras clave: Antipsicoticos, Trastorno depresivo mayor, Trastorno depresivo resistente al tratamiento, Quinolonas, Tiofenos. Resumen: To evaluate efficacy, safety, and tolerability of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive disorder (as defined by DSM-IV-TR criteria) with inadequate response to ADTs. Link: ./index.php?lvl=notice_display&id=21882 Adverse effects of second-generation antipsychotics as adjuncts to antidepressants / Michael E. Thase en Psychiatric Clinics of North America, Año 2016 - Vol.39 - No.3 (Septiembre)
[artículo]
Título : Adverse effects of second-generation antipsychotics as adjuncts to antidepressants : are the risks worth the benefits? Tipo de documento: texto impreso Autores: Michael E. Thase, Autor Fecha de publicación: 2020 Artículo en la página: pp. 477-486 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Efectos adversos, Antipsicóticos de segunda generación, Terapia complementaria, Riesgos, Beneficios Resumen: Over the past decades, several adjunctive therapies have been introduced for treatment-resistant depression (TRD), and these strategies have ebbed and flowed in popularity. Currently, adjunctive therapy with the second-generation antipsychotics (SGAs) is most commonly used by psychiatrists. Link: ./index.php?lvl=notice_display&id=24118
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.3 (Septiembre) . - pp. 477-486[artículo] Adverse effects of second-generation antipsychotics as adjuncts to antidepressants : are the risks worth the benefits? [texto impreso] / Michael E. Thase, Autor . - 2020 . - pp. 477-486.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.3 (Septiembre) . - pp. 477-486
Palabras clave: Efectos adversos, Antipsicóticos de segunda generación, Terapia complementaria, Riesgos, Beneficios Resumen: Over the past decades, several adjunctive therapies have been introduced for treatment-resistant depression (TRD), and these strategies have ebbed and flowed in popularity. Currently, adjunctive therapy with the second-generation antipsychotics (SGAs) is most commonly used by psychiatrists. Link: ./index.php?lvl=notice_display&id=24118 Aripiprazole monotherapy in nonpsychotic bipolar i depression / Michael E. Thase en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 1 (Febrero)
[artículo]
Título : Aripiprazole monotherapy in nonpsychotic bipolar i depression : Results of 2 randomized, placebo-controlled studies Tipo de documento: texto impreso Autores: Michael E. Thase, Autor ; Alan Jonas, Autor ; Arif Khan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 13-20 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Trastorno bipolar, Trastorno depresivo mayor, Determinación del criterio de valoración, Piperazinas, Quinolonas. Resumen: Although most treatment research on bipolar disorder has focused on mania, depressive episodes occur more frequently among patients with bipolar disorder. Here, we report the results of 2 identically designed, 8-week, multicenter, randomized, double-blind, placebo-controlled studies (CN138-096 and CN138-146) to evaluate the efficacy and safety of aripiprazole monotherapy in outpatients with bipolar I disorder experiencing a major depressive episode without psychotic features. Link: ./index.php?lvl=notice_display&id=30867
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 1 (Febrero) . - pp. 13-20[artículo] Aripiprazole monotherapy in nonpsychotic bipolar i depression : Results of 2 randomized, placebo-controlled studies [texto impreso] / Michael E. Thase, Autor ; Alan Jonas, Autor ; Arif Khan, Autor . - 2023 . - pp. 13-20.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 1 (Febrero) . - pp. 13-20
Palabras clave: Antipsicóticos, Trastorno bipolar, Trastorno depresivo mayor, Determinación del criterio de valoración, Piperazinas, Quinolonas. Resumen: Although most treatment research on bipolar disorder has focused on mania, depressive episodes occur more frequently among patients with bipolar disorder. Here, we report the results of 2 identically designed, 8-week, multicenter, randomized, double-blind, placebo-controlled studies (CN138-096 and CN138-146) to evaluate the efficacy and safety of aripiprazole monotherapy in outpatients with bipolar I disorder experiencing a major depressive episode without psychotic features. Link: ./index.php?lvl=notice_display&id=30867 Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder / Michael E. Thase en The British Journal of Psychiatry, Año 2011 - Vol. 199 - No. 6 (Diciembre)
[artículo]
Título : Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder : use of a mixture model Tipo de documento: texto impreso Autores: Michael E. Thase, Autor ; Klaus G. Larsen, Autor ; Sidney H. Kennedy, Autor Fecha de publicación: 2021 Artículo en la página: pp. 501 - 507 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Citalopram, Trastorno depresivo Resumen: There is controversy about the implications of relatively small average drug–placebo differences observed in randomised controlled trials of antidepressant medications. Link: ./index.php?lvl=notice_display&id=27526
in The British Journal of Psychiatry > Año 2011 - Vol. 199 - No. 6 (Diciembre) . - pp. 501 - 507[artículo] Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder : use of a mixture model [texto impreso] / Michael E. Thase, Autor ; Klaus G. Larsen, Autor ; Sidney H. Kennedy, Autor . - 2021 . - pp. 501 - 507.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The British Journal of Psychiatry > Año 2011 - Vol. 199 - No. 6 (Diciembre) . - pp. 501 - 507
Palabras clave: Antidepresivos, Citalopram, Trastorno depresivo Resumen: There is controversy about the implications of relatively small average drug–placebo differences observed in randomised controlled trials of antidepressant medications. Link: ./index.php?lvl=notice_display&id=27526 Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine / Michael E. Thase en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 2 (Abril)
PermalinkChoosing medications for treatment-resistant depression based on mechanism of action / Michael E. Thase en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.6 (Junio)
PermalinkEfficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder / Michael E. Thase en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.9 (Septiembre)
PermalinkEfficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant / Eduard Vieta Pascual en European Neuropsychopharmacology, Año 2014 - Vol. 24 - No.4 (Abril)
PermalinkHandbook of outpatient treatment of adults / Michael E. Thase
PermalinkImproving Depression Outcome by Patient-Centered Medical Management / A. John Rush en The American Journal of Psychiatry, Año 2018 - Vol. 175 - No.12 (Diciembre)
PermalinkImproving the Efficiency of Psychotherapy for Depression / Michael E. Thase en The American Journal of Psychiatry, Año 2018 - Vol. 175 - No. 3 (Marzo)
PermalinkA meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults / Michael E. Thase en European Neuropsychopharmacology, Año 2016 - Vol. 26 - No. 6 (Junio)
PermalinkPharmacotherapy for the treatment of acute bipolar II depression / Holly A. Swartz en The Journal of Clinical Psychiatry, Año 2011 - Vol.72 - No. 3 (Marzo)
PermalinkPsychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression / Holly A. Swartz en The Journal of Clinical Psychiatry, Año 2018 - Vol. 79 - No.2 ([12/06/2018])
Permalink